Truist has downgraded Merck (NYSE:MRK) to hold from buy, citing upcoming loss of market exclusivity and continuing headwinds ...
The stock's fall snapped a two-day winning streak.
WuXi Biologics’ move to sell the facility could strengthen the company’s cash flow and margins as it navigates global ...
If approved, Pfizer’s sasanlimab will distinguish itself from Merck’s blockbuster Keytruda as the first PD-1 inhibitor ...
Truist downgraded Merck (MRK) to Hold from Buy with a price target of $110, down from $130, as part of a broader research note previewing FY25 ...
Merck Forest & Farmland Center will be hosting two upcoming events, an Animal Tracking Hike on Saturday, January 11 from 10 a ...
WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese ...
Colorectal cancer (CRC) is the third most common cancer and the second most common cause of cancer deaths worldwide. In 2023, ...
Atropos Health, a pioneer in translating real-world clinical data into real-world evidence (RWE) for decision-making, today ...